Stifel initiated coverage of Edgewise Therapeutics (EWTX) with a Hold rating and $30 price target The firm says that while Edgewise has “very interesting science” with two clinical-stage assets, its thesis reflects a view that clinical data for both EDG-7500 and sevasemten are early, and there remains “real risk” to the “target-product-profile” for each. The window to clearly differentiate from aficamten is narrow and the path to doing so “is tricky,” the analyst tells investors in a research note.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EWTX:
- Edgewise Therapeutics price target raised to $50 from $45 at Evercore ISI
- Edgewise Therapeutics Reports Promising Phase 2 Trial Results
- Edgewise Therapeutics price target raised to $50 from $44 at Leerink
- Morning Movers: Viridian and Edgewise jump following successful trials
- Edgewise reports CANYON Phase 2 trial of sevasemten meets primary endpoint